DELIVERXD HEALTHCARE

Prescribing Guide

Provider-facing quick reference — patient-specific GLP-1 compounding, 2026

Documenting patient-specific need

- [ ] Different dosage form/strength, clinically necessary
- [ ] Documented allergy/intolerance to an inactive ingredient
- [ ] Combination product for a specific, documented need
- [ ] NOT cost or general unavailability alone

Eligibility screening

- **Indication:** BMI ≥ 30, or ≥ 27 with qualifying comorbidity
- **Screen for:** MTC/MEN2 history, pancreatitis history, pregnancy, known hypersensitivity
- **Baseline:** weight/BMI, BP, labs per medical director protocol
- **Consent:** benefits, risks, alternatives, compounded-product acknowledgment

General titration reference

Mirrors published step-up cadence for reference products. Prescriber sets actual dose/increments against compounded concentration.

Week	Semaglutide	Tirzepatide
1–4	Low starting dose	Low starting dose
5–8	1st step-up, if tolerated	1st step-up, if tolerated
9–12	2nd step-up, if tolerated	2nd step-up, if tolerated
13+	Maintenance range	Maintenance range

Follow-up cadence

- Baseline → 4 weeks → 8 weeks → 12 weeks → monthly, or per protocol
- Reassess documented clinical need at every visit

Discontinuation criteria

- Inadequate response after appropriate trial
- Intolerable side effects unmanaged by adjustment
- No longer meets documented clinical-need criteria

PREVIEW
PREVIEW

For educational/operational support only; not legal or clinical advice.
Dosing decisions remain the prescriber's clinical judgment. — Full kit available at providers.deliverxdfl.com